Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials

Radiopharmaceutical therapy (RPT) has rapidly evolved into a key precision-oncology modality, with radioligands now approved or in late-stage development for multiple solid tumors, including neuroendocrine and prostate cancers. RPT with [ 177 Lu]Lu-PSMA (Prostate-Specific Membrane Antigen) has recently been approved as a life-prolonging treatment for metastatic castration-resistant prostate cancer (mCRPC), but its clinical use still relies on nonpersonalized, empirically chosen fixed schedules. Here, we develop a mechanistic, patient-personalizable mathematical model simulating mCRPC response and organ-at-risk toxicity during [ 177 Lu]Lu-PSMA RPT. The model integrates tumor growth dynamics, radiobiological response, and organ-resolved pharmacokinetics inferred from mass data and standardized uptake values obtained from positron emission tomography studies. Parameters were derived from the literature, although the framework allows personalization by fitting to patient-specific data, such as imaging and prostate-specific antigen levels. Analytical threshold analysis identified a critical activity scale governing net tumor control, while simulations of a representative virtual patient (VP) illustrated the model’s coupled tumor and activity dynamics. Global sensitivity analysis identified tumor growth, uptake, and radiosensitivity parameters as key drivers of interpatient variability. Using VP cohorts generated via stochastic parameter sampling, we conducted in silico trials and benchmarked the model against published dosimetry and survival data for [ 177 Lu]Lu-PSMA trials. Convergence testing supported the use of cohorts of 500 VPs for stable population-level estimates. We then explored dosing and scheduling strategies to quantify efficacy–toxicity trade-offs. Consolidated regimens with fewer, higher-activity injections improved overall survival (OS) in silico but increased toxicity, especially in kidneys. Cycle length had a weaker influence on OS within a 2–9 week window, while it clearly affected toxicity, whereas excessive delays (> 12 weeks) markedly reduced efficacy. These methodological findings illustrate how mechanistic modeling and in silico trials can inform the design and personalization of RPT regimens.

Authors

Institutions

Publication Details

Journal
PLoS Computational Biology
Published
2026-11-18
DOI
https://doi.org/10.1371/journal.pcbi.1013847
Citations
2
Primary Topic
Radiopharmaceutical Chemistry and Applications
Type
article
Field-Weighted Citation Impact
4.65

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials

José García Otero, Gabriel F. Calvo, Matteo Italia, Victor M. Pérez-Garcı́a et al.
2 citations
PLoS Computational Biology
Radiopharmaceutical Chemistry and Applications
4.65
article

Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials

José García Otero, Gabriel F. Calvo, Matteo Italia, Victor M. Pérez-Garcı́a, Silvia Bordel-Vozmediano
article en
2 citations

Abstract

Radiopharmaceutical therapy (RPT) has rapidly evolved into a key precision-oncology modality, with radioligands now approved or in late-stage development for multiple solid tumors, including neuroendocrine and prostate cancers. RPT with [ 177 Lu]Lu-PSMA (Prostate-Specific Membrane Antigen) has recently been approved as a life-prolonging treatment for metastatic castration-resistant prostate cancer (mCRPC), but its clinical use still relies on nonpersonalized, empirically chosen fixed schedules. Here, we develop a mechanistic, patient-personalizable mathematical model simulating mCRPC response and organ-at-risk toxicity during [ 177 Lu]Lu-PSMA RPT. The model integrates tumor growth dynamics, radiobiological response, and organ-resolved pharmacokinetics inferred from mass data and standardized uptake values obtained from positron emission tomography studies. Parameters were derived from the literature, although the framework allows personalization by fitting to patient-specific data, such as imaging and prostate-specific antigen levels. Analytical threshold analysis identified a critical activity scale governing net tumor control, while simulations of a representative virtual patient (VP) illustrated the model’s coupled tumor and activity dynamics. Global sensitivity analysis identified tumor growth, uptake, and radiosensitivity parameters as key drivers of interpatient variability. Using VP cohorts generated via stochastic parameter sampling, we conducted in silico trials and benchmarked the model against published dosimetry and survival data for [ 177 Lu]Lu-PSMA trials. Convergence testing supported the use of cohorts of 500 VPs for stable population-level estimates. We then explored dosing and scheduling strategies to quantify efficacy–toxicity trade-offs. Consolidated regimens with fewer, higher-activity injections improved overall survival (OS) in silico but increased toxicity, especially in kidneys. Cycle length had a weaker influence on OS within a 2–9 week window, while it clearly affected toxicity, whereas excessive delays (> 12 weeks) markedly reduced efficacy. These methodological findings illustrate how mechanistic modeling and in silico trials can inform the design and personalization of RPT regimens.

PLoS Computational BiologyVol. 22(11)
University of Castilla-La Mancha (ES)
Ministerio de Ciencia e Innovación, Universidad de Castilla-La Mancha, Junta de Comunidades de Castilla-La Mancha, European Regional Development Fund, Agencia Estatal de Investigación
Good health and well-being
Openalex Percentile: Top 9%
Radiopharmaceutical Chemistry and Applications
4.65
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon